Gland Pharma Limited, a leading injectable-focused pharmaceutical company, has announced the approval of its Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill), by the United States Food and Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan®, held by UPJOHN US 2 LLC.
Latanoprost Ophthalmic Solution is commonly used to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. With the recent USFDA approval, Gland Pharma plans to launch this product in the U.S. market through its marketing partners in fiscal year 2025. According to IQVIA, the product generated US sales of approximately USD 111.6 million for the 12 months ending December 2023, highlighting the product’s strong market potential.
Founded in 1978 in Hyderabad, Gland Pharma has evolved into one of the world’s largest injectable-focused pharmaceutical companies, expanding its presence in over 60 countries, including the U.S., Europe, Canada, Australia, and India. The company’s diverse portfolio and focus on high-quality injectable medications have made it a trusted partner in the global healthcare landscape.
In the meantime today, Gland Pharma Limited opened at ₹1,784.70, with a daily high of ₹1,829.45 and a low of ₹1,777.55. Over the past 52 weeks, the stock has reached a high of ₹2,220.95 and a low of ₹1,585.70.
